SemaThera
Business Services · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Westmount Square 1 Ste 800, Montreal, Qu...Website
www.semathera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About SemaThera
SemaThera Inc. is focused on developing innovative treatments for diabetic and other retinal degenerative diseases, addressing the significant impact of diabetes on vision. The company has conducted over a decade of research into the role of semaphorin 3A in diabetic retinopathy, leading to the creation of biological traps that sequester harmful proteins and cytokines. Their products aim to reduce retinal vascular leakage, inflammation, and promote re-vascularization in affected patients. SemaThera collaborates with leading organizations, including a partnership with Roche, to advance their therapeutic solutions.Explore more
SemaThera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SemaThera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if SemaThera is spiking on competitors!
Click to see if SemaThera had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when SemaThera launches new products
Congratulate Masked Content for being promoted to Masked Content at SemaThera
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on SemaThera recently announced quarterly report
Check if SemaThera has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once SemaThera has new funding data
SemaThera, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined SemaThera as Masked Content
Find 2 more new buyers
Compare Similar Companies to SemaThera
Compare insights from companies similar to SemaThera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SemaThera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SemaThera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SemaThera.
SemaThera Tech Stack
A closer look at the technologies used by SemaThera
SemaThera News & Media
SemaThera conclut un accord de collaboration de recherche et de licence exclusive avec Roche
Montréal, Québec--(BUSINESS WIRE)--SemaThera Inc. a annoncé aujourd'hui la signature d'un accord de collaboration et de licence de recherche pluriannuel avec Roche. Le partenariat se concentrera sur le développement d’une nouvelle classe prometteuse de produits biologiques de SemaThera pour le traitement de la rétinopathie diabétique et d’autres maladies rétiniennes ischémiques. « Nous sommes très enthousiastes à l'idée de combiner nos connaissances de la biologie sous-jacente des nouveaux antaSemaThera Board Names Garth Cumberlidge as President & CEO
MONTREAL--(BUSINESS WIRE)--#amorchem--SemaThera Inc., announces today that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retinopathies. Its lead compound, ST-102, is a bispecific recombinant protein trap, binding both VEGF and SEMA3A. “AmorChem is proud to welcome Garth CumberliSemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan
MONTREAL--(BUSINESS WIRE)--#amorchem--SemaThera Inc announces today the closing of a $2MUS co-investment from Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the development of its lead candidate, ST-102, in preparation for a clinical trial application in diabetic macular edema (DME). As part of this financing, SemaThera also signed an exclusive option of license with Senju. Under the terms of the agreement, Senju acquired the option rights to exclusively develop and market SemaThera’s ST-1
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding SemaThera
Sign Up For FreeTo access detailed company insights
SemaThera Inc. is focused on developing innovative treatments for diabetic and other retinal degenerative diseases, addressing the significant impact of diabetes on vision. The company has conducted over a decade of research into the role of semaphorin 3A in diabetic retinopathy, leading to the creation of biological traps that sequester harmful pr... Read More
